Zanganeh Mahkam, co-CEO of Summit Therapeutics, has purchased shares of the company's stock valued at $1.46 million. This acquisition reflects Mahkam's confidence in the company's future prospects. The transaction is part of a broader trend of executive stock purchases, which can indicate a positive outlook on the company's performance. Details regarding the specific number of shares acquired and the timing of the purchase have not been disclosed.
Related Articles
Don't miss out on breaking stories and in-depth articles.